Compare AbbVie Inc (ABBV) vs Trump Media and Technology Group Corp (DJT) Price & Performance

AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.

The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.

DJT trades at $8.66, up 1.41% today, with a bullish technical signal from moving averages despite neutral oscillators. Fundamentally, the company reported minimal revenue of $3.68M in 2025 with a massive net loss of -$712M, resulting in negative profit margins and ROE. Recent news highlights significant stock declines, with the company's market value dropping nearly 75% from its peak amid strategic shifts including a planned merger with TAE Technologies.

The outlook remains highly speculative with severe profitability challenges offset by potential catalysts from the TAE merger. Key risks include persistent losses, minimal revenue growth, and high volatility. Institutional sentiment is cautious given the extreme valuation metrics and operational uncertainties facing the social media platform.